Mirum Pharmaceuticals
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
989 E Hillsdale Blvd Ste 300, Foster Cit...Phone Number
(650) 667-4085Website
www.mirumpharma.comRevenue
$618.1 MillionStock Symbol
MIRMIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is dedicated to creating life-changing therapies for patients with liver diseases. Mirum Pharmaceuticals, Inc is a US based rare disease biotechnology company focused on developing and commercializing therapies for serious liver and metabolic disorders, especially cholestatic liver diseases and other rare pediatric and adult conditions. Its key products include therapies for Alagille syndrome and other bile-acid related disorders.Explore more
Mirum Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
SN
Senior VP, Clinical Operations
JL
Vice President, Global Patient Advocacy
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mirum Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Mirum Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Mirum Pharmaceuticals
Earning: See what the market has to say on Mirum Pharmaceuticals recently announced quarterly report
Mirum Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Mirum Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Check if Mirum Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Mirum Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Mirum Pharmaceuticals has new funding data
Recommended Actions
Find VP level buyers at Mirum Pharmaceuticals
Find more new buyers
Compare Similar Companies to Mirum Pharmaceuticals
Compare insights from companies similar to Mirum Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$19.9M
51-200
Private
$300M
2016
RC
Ryan CarteExecutive Vice President & General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
Mirum Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Mirum Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mirum Pharmaceuticals.
Mirum Pharmaceuticals financials insights
Gather financial insights about Mirum Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$68.5M
Mirum Pharmaceuticals Tech Stack
A closer look at the technologies used by Mirum Pharmaceuticals
See more technologies
Most Recent Scoops
Project
Mirum Pharmaceuticals has been given the Breakthrough Therapy Designation by the FDA for volixibat in cholestatic pruritus due to primary sclerosing cholangitis (PSC), recognizing the potential of volixibat to address a serious unmet medical need in PSC patients.
Pharmaceuticals
Earnings
Mirum Pharmaceuticals has reported net product sales of $129 million for LIVMARLI in Q2, with the US contributing $92 million, driven by continued new patient starts, sustained persistence on therapy, and weight-based dose increases in Alagille syndrome.
Earnings, Finance
Pain Point
Mirum Pharmaceuticals is experiencing a delay in its planned NDA submission for volixibat, after the FDA recommended conducting a Phase III study following a pre-NDA discussion based on the VISTA study, indicating the two parties are not currently aligned on the submission package. Mirum is now targeting an NDA submission in H1 of next year while engaging in further discussions with the FDA to supplement its planned submission.
Pharmaceuticals, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Earnings, Business Finance, Finance
Mirum Pharmaceuticals News & Media
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional business development activity expanding its portfolio. Speaking at RBC Capital Markets’ 20Mirum Pharma: A Rare Disease Growth Story to Watch
Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech companyMirum Pharmaceuticals Says Volixibat Phase IIb VISTAS Hits Endpoint, Cuts PSC Itch vs Placebo
Mirum Pharmaceuticals (NASDAQ:MIRM) said its Phase IIb VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC) met its primary endpoint, showing a statistically significant reduction in cholestatic pruritus compared with placebo, according to executives on the company’s businPrediction: Buying This Biotech Stock Today Could Set You Up for Life
This small biotech could grow much larger with some good news from its pipeline.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mirum Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Mirum Pharmaceuticals is dedicated to creating life-changing therapies for patients with liver diseases. Mirum Pharmaceuticals, Inc is a US based rare disease biotechnology company focused on developing and commercializing therapies for serious liver and metabolic disorders, especially cholestatic liver diseases and other rare pediatric and adult c... Read More
